Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease that is caused by a novel phlebovirus in the *Bunyaviridae* family. This virus has been named severe fever with thrombocytopenia syndrome virus (SFTSV). The disease was first reported during 2009 in China, where it is most prevalent in the Hunan, Hubei, and Shandong provinces, which are located at a similar latitude to that of South Korea and Japan ([@R1]). SFTS is mainly transmitted to humans by SFTSV-infected ticks, most frequently *Haemaphysalis longicornis* ([@R2]). However, person-to-person transmission by direct contact with infected blood or body fluid has also been reported ([@R3],[@R4]).

The clinical symptoms of SFTS include fever; gastrointestinal (GI) symptoms (e.g., diarrhea and vomiting); leukocytopenia and thrombocytopenia; bleeding tendency; and neurologic symptoms. The incubation period for SFTS is 1--2 weeks, and illness progresses through 3 stages: fever, multiorgan dysfunction, and convalescence. No effective treatment for SFTS has been established ([@R5]).

In South Korea, the laboratory diagnostic system for SFTS was established during March 2013, and the presence of SFTSV among *H. longicornis* ticks was confirmed by using samples from ticks that were collected during 2011--2012 ([@R6]). Based on the nationwide surveillance reports for SFTS and its designation as a notifiable infectious disease, the first SFTS case was retrospectively confirmed in May 2013, after the patient's death in 2012 ([@R7]). However, because of the novel nature of this system, the clinical and demographic characteristics of patients in South Korea infected with SFTS are not well understood. Therefore, this study evaluated the characteristics and factors that were associated with SFTS-related fatalities in South Korea, as reported during 2013.

Methods
=======

Surveillance System and Case Definition
---------------------------------------

A passive hospital-based surveillance system for SFTS was initiated nationwide in South Korea during March 2013. Physicians were advised to request SFTSV testing for patients with known clinical manifestations of SFTS, including fever (body temperature [\>]{.ul}38.0°C), thrombocytopenia, leukocytopenia, and GI symptoms. Each patient's enrollment for SFTSV testing was dependent on the physician's clinical suspicion of SFTS. Serum samples from 301 patients admitted on the basis of physician referrals at 125 hospitals throughout Korea were collected and tested. Case-patients were defined as patients who had clinical symptoms and were confirmed to have SFTSV by virologic testing at the Korea Centers for Disease Control and Prevention (KCDC). This study did not require an institutional ethics review because it was conducted under the Infectious Disease Control and Prevention Act in South Korea.

Laboratory Testing
------------------

All acute-phase serum samples were tested to detect the SFTSV medium segment gene by one-step reverse transcription PCR, by using DiaStar 2× OneStep reverse transcription PCR Pre-Mix Kit (SolGent, Daejeon, South Korea), as described ([@R8]). The PCR primers were MF3 (5′-GATGAGATGGTCCATGCTGATTCT-3′) and MR2 (5′-CTCATGGGGTGGAATGTCCTCAC-3′). The PCR conditions were an initial step of 30 min at 50°C for reverse transcription; 15 min at 95°C for denaturation; 35 cycles of 20 s at 95°C, 40 s at 58°C, and 30 s at 72°C; and a final extension step of 5 min at 72°C.

Epidemiologic Investigation
---------------------------

We also performed an epidemiologic investigation of patients in whom SFTS was suspected immediately after the SFTSV testing was requested by their physicians. KCDC Epidemic Intelligence Service officers interviewed the patients and their physicians using a standardized questionnaire that evaluated demographic characteristics, exposure history, clinical symptoms, and laboratory results. Patients were also questioned regarding their exposure history within the month before their onset of symptoms. Multiple activities were documented, including agricultural and forestry work, mountain climbing, and visits to a family grave. The date of the tick bite was self-reported when the patient was aware of a bite or if the patient participated in only 1 exposure-related activity over a short period of time. In addition, after the death or discharge of confirmed case-patients during September 2013--January 2014, the clinical course and prognosis were investigated by reviewing medical records. The date for clinical suspicion of SFTS was recorded as the date reported to the KCDC.

Statistical Analysis
--------------------

We obtained median regional population data during 2013 from Statistics Korea (<http://www.kostat.go.kr>) to calculate the regional incidences during 2013. These incidences were then overlaid on a map of South Korea by using bio-geographic information system software (DIVA-GIS 7.5; <http://www.diva-gis.org>). We used the Fisher exact test or the Mann-Whitney U test to compare the prognoses of patients with SFTS. All statistical analyses were performed by using SAS software version 9.2 (SAS Institute, Cary, NC, USA), and statistical significance was set at p\<0.05.

Results
-------

During 2013, a total of 36 hospitalized patients were confirmed to have SFTS. One case was excluded because the patient's disease onset occurred during 2012. Thus, 35 cases from 20 hospitals were included in our analysis.

Demographic Characteristics
---------------------------

Symptom onset occurred during May--November 2013; a peak of symptoms among 9 (26%) patients occurred in June. Similar patterns were observed among the SFTS case-patients in our study ([Figure 1](#F1){ref-type="fig"}, panel A) and the number of *H. longicornis* ticks that were collected each month by Park et al. during 2011--2012 ([@R6]) ([Figure 1](#F1){ref-type="fig"}, panel B). Peaks of symptoms among patients occurred in June 2013, and peaks of the number of ticks collected occurred in May 2011 and May 2012.

![Comparison of epidemic curve for severe fever with thrombocytopenia syndrome cases identified during 2013 and the number of *Haemaphysalis longicornis* ticks collected per month during 2011 and 2012, South Korea. A) Number of cases of severe fever with thrombocytopenia syndrome, by month of onset. B) Combined number of *H. longicornis* ticks collected, by month ([@R6]).](14-1928-F1){#F1}

The overall incidence of SFTS during 2013 was 0.7 cases/1 million persons. Geographic differences were documented in the incidences in 25 cities; higher incidences were observed in the southern regions, including Jeju Province ([Figure 2](#F2){ref-type="fig"}).

![Geographic distribution of severe fever with thrombocytopenia syndrome cases, South Korea, 2013. Shading indicates incidence of cases per 1 million residents. Black circles indicate the approximate residential regions of the 16 case-patients who died.](14-1928-F2){#F2}

The case-patient group comprised 18 women (51%) and 17 men (49%). The median age was 69 (range 28--84) years, and age was significantly higher among those who died (range 62--82 years; p = 0.026). Twenty-six (74%) case-patients resided in rural areas, and 25 (71%) were farmers. A trace of a tick bite was found on 11 (31%) case-patients, and 4 (13%) had recognized the tick bite before their hospital admission. The most common exposure-related activity was agricultural work (n = 20, 61%), followed by forestry work (n = 7, 21%), mountain climbing (n = 6, 18%), and visiting a family member's grave (n = 3, 9%). The agricultural work was performed in dry fields by 16 (80%) of 20 case-patients and forestry work was done in orchards by 5 (71%) of 7 case-patients ([Table 1](#T1){ref-type="table"}).

###### Characteristics of hospitalized case-patients with confirmed severe fever with thrombocytopenia syndrome, by outcome, South Korea, 2013

  Characteristics                                                                                                                                                                                                                                                                                                          No. (% or range)   p value                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ --------------- ------------- --------
  Sex                                                                                                                                                                                                                                                                                                                                                                       
  M                                                                                                                                                                                                                                                                                                                        17 (49)            7 (44)          10 (53)       0.738
  F                                                                                                                                                                                                                                                                                                                        18 (51)            9 (56)          9 (47)        
  Age, y                                                                                                                                                                                                                                                                                                                   69 (28--84)        73.5 (62--82)   61 (28--84)   0.026
  Residence                                                                                                                                                                                                                                                                                                                                                                 
  Rural                                                                                                                                                                                                                                                                                                                    26 (74)            11 (69)         15 (79)       0.700
  Urban                                                                                                                                                                                                                                                                                                                    9 (26)             5 (31)          4 (21)        
  Occupation                                                                                                                                                                                                                                                                                                                                                                
  Farmers                                                                                                                                                                                                                                                                                                                  25 (71)            12 (75)         13 (68)       0.723
  Others                                                                                                                                                                                                                                                                                                                   10 (29)            4 (25)          6 (32)        
  Medical history                                                                                                                                                                                                                                                                                                                                                           
  Diabetes mellitus                                                                                                                                                                                                                                                                                                        11 (31)            5 (31)          6 (32)        1.000
  Hypertension                                                                                                                                                                                                                                                                                                             18 (51)            9 (60)          9 (47)        0.738
  Hepatitis B                                                                                                                                                                                                                                                                                                              2 (6)              2 (13)          0 (0)         0.202
  Tuberculosis                                                                                                                                                                                                                                                                                                             1 (3)              1 (6)           0 (0)         0.457
  Trace of tick bite                                                                                                                                                                                                                                                                                                       11 (31)            5 (31)          6 (32)        1.000
  Recognition of tick bite, n = 32                                                                                                                                                                                                                                                                                         4 (13)             2 (14)          2 (11)        1.000
  Exposure-related activities, n = 33†                                                                                                                                                                                                                                                                                                                                      
  Agricultural work                                                                                                                                                                                                                                                                                                        20 (61)            9 (60)          11 (61)       1.000
  Forestry work                                                                                                                                                                                                                                                                                                            7 (21)             4 (27)          3 (17)        0.674
  Mountain climbing                                                                                                                                                                                                                                                                                                        6 (18)             1 (7)           5 (28)        0.186
  Visits to family members\' grave                                                                                                                                                                                                                                                                                         3 (9)              2 (13)          1 (6)         0.579
  Time elapsed, d                                                                                                                                                                                                                                                                                                                                                           
  From onset to admission                                                                                                                                                                                                                                                                                                  4 (1--9)           3.5 (1--7)      4 (2--9)      0.659‡
  From onset to clinical suspicion§                                                                                                                                                                                                                                                                                        7 (3--22)          6.5 (3--11)     7 (3--22)     0.612‡
  From onset to death                                                                                                                                                                                                                                                                                                      ND¶                10.5 (4--32)    ND            ND
  From onset to discharge                                                                                                                                                                                                                                                                                                  ND                 ND              18 (10--49)   ND
  \*ND, no data available. †Fisher exact test was used to compare groups, unless otherwise indicated. ‡Multiple responses were allowed. §Mann-Whitney U test was used to compare groups. ¶Days to clinical suspicion were determined based on the day of report to the Korea Centers for Disease Control and Prevention.                                                    

The incubation period was available for 8 patients; the median was 9 (range 5--16) days. Median time from symptom onset to hospital admission was 4 (range 1--9) days and from symptom onset to clinical suspicion was 7 (range 3--22) days. We found no substantive differences in time from symptom onset to admission and to clinical suspicion between the group of persons who died and those who recovered. Twenty-four (69%) of the 35 patients with SFTS were admitted to intensive care units, and 16 (46%) died. The median survival time among the 16 was 10.5 (range 4--32) days; 11 (69%) patients died within 2 weeks after symptom onset. Among patients who survived, median time from symptom onset to discharge was 18 (range 10--49) days ([Table 1](#T1){ref-type="table"}).

The cohort included 1 family cluster, which consisted of an uncle and nephew. They did not live in the same village and did not have contact with each other after symptom onset. However, within 2 weeks before symptom onset, both had visited the same family member's grave on a mountain and had mowed the grass.

Clinical Characteristics and Prognoses
--------------------------------------

The clinical characteristics of the 35 SFTS case-patients during the course of the illness are shown in [Table 2](#T2){ref-type="table"}. All patients experienced fever or chills, and other common symptoms included GI symptoms (n = 33, 94%), neurologic symptoms (n = 27, 77%), fatigue (n = 26, 74%), myalgia (n = 19, 54%), and hemorrhagic manifestations (n = 12, 34%). Among the 32 patients with medical records for the first 7 days after disease onset, all patients had a fever within 7 days of symptom onset. A high fever (≥39°C) was documented for 7 (22%) patients, although no significant difference was observed related to occurrence of fever among those who died and those who recovered (p = 0.195). Lymphadenopathy was identified by physical examination on admission on the neck, face, left thigh, left axilla, or left inguinal area of 5 (14%) patients.

###### Clinical characteristics of hospitalized case-patients with confirmed severe fever with thrombocytopenia syndrome, by outcome, South Korea, 2013\*

  Characteristics                              No. (%) case-patients   p value†              
  -------------------------------------------- ----------------------- ---------- ---------- -------
  Fever/chills                                 35 (100)                16 (100)   19 (100)   1.000
  Fever, n = 32                                                                              
  ≤39.0°C                                      25 (78)                 9 (64)     16 (89)    0.195
  \>39.0°C                                     7 (22)                  5 (36)     2 (11)     NA
  Fatigue                                      26 (74)                 11 (69)    15 (79)    0.700
  Myalgia                                      19 (54)                 9 (56)     10 (53)    1.000
  Headache                                     12 (34)                 4 (25)     8 (42)     0.476
  Cough                                        7 (20)                  3 (19)     4 (21)     1.000
  Sputum                                       9 (26)                  3 (19)     6 (32)     0.460
  Lymphadenopathy on physical examination      5 (14)                  1 (6)      4 (21)     0.347
  Lymph node enlargement found by CT, n = 32   20 (63)                 7 (54)     13 (68)    0.473
  Gastrointestinal symptoms                                                                  
  Overall                                      33 (94)                 15 (94)    18 (95)    1.000
  Anorexia                                     21 (60)                 8 (50)     13 (68)    0.317
  Nausea                                       16 (46)                 5 (31)     11 (58)    0.176
  Abdominal pain                               9 (26)                  6 (38)     3 (16)     0.245
  Diarrhea                                     22 (63)                 12 (75)    10 (53)    0.293
  Vomiting                                     15 (43)                 6 (38)     9 (47)     0.734
  Diarrhea/vomiting                            26 (74)                 13 (81)    13 (68)    0.460
  Neurologic symptoms                                                                        
  Overall                                      27 (77)                 15 (94)    12 (63)    0.047
  Within 7 d after disease onset               20 (57)                 14 (88)    6 (32)     0.002
  Slurred speech                               9 (26)                  7 (44)     2 (11)     0.050
  Decreased level of consciousness             26 (74)                 15 (94)    11 (58)    0.022
  Convulsions                                  8 (23)                  6 (38)     2 (11)     0.105
  Hemorrhagic manifestations                                                                 
  Overall                                      12 (34)                 8 (50)     4 (21)     0.090
  Gross hematuria                              2 (6)                   1 (6)      1 (5)      1.000
  Petechiae                                    3 (9)                   1 (6)      2 (11)     1.000
  Gingival bleeding                            5 (14)                  3 (19)     2 (11)     0.642
  Hematemesis                                  2 (6)                   1 (6)      1 (5)      1.000
  Hematochezia                                 1 (3)                   1 (6)      0 (0)      0.457
  Melena                                       4 (11)                  4 (25)     0 (0)      0.035
  Treatment                                                                                  
  Ribavirin                                    9 (26)                  6 (38)     3 (16)     0.245
  IVIG                                         7 (20)                  5 (31)     2 (11)     0.208
  Plasmapheresis                               7 (20)                  4 (25)     3 (16)     0.677
  CRRT                                         10 (29)                 9 (56)     1 (5)      0.002

\*NA, not applicable; CT, computed tomography; IVIG, intravenous immunoglobulin; CRRT, continuous renal replacement therapy. †Fisher exact test was used to compare groups.

The most common GI symptoms among all patients were diarrhea (n = 22, 63%), anorexia (n = 21, 60%), nausea (n = 16, 46%), and vomiting (n = 15, 43%). Both diarrhea and vomiting were reported for 26 (74%) patients; most (25/26, 96%) experienced diarrhea or vomiting within 1 week after symptom onset, and 18 (51%) patients had diarrhea or vomiting at the time of admission. However, no substantive differences in the occurrence of GI symptoms were observed for those who died compared with those who recovered.

Decreased level of consciousness (n = 26, 74%) was the most frequent neurologic symptom, followed by slurred speech (n = 9, 26%) and convulsion (n = 8, 23%). Neurologic symptoms occurred at a median of 6 days after symptom onset (range 2--10 days). On admission, 3 patients (9%) had neurologic symptoms. The group of case-patients who died had a significantly higher number of members who had neurologic symptoms (p = 0.047) and exhibited significantly more frequent neurologic symptoms that occurred within 7 days (p = 0.002). Decreased level of consciousness (p = 0.050) and slurred speech (p = 0.022) were significantly more common among those who died, although the frequency of convulsion was similar for both groups (p = 0.105).

The only hemorrhagic manifestation that occurred with a significant difference among those who died and those who recovered was melena (p = 0.035). None of the treatments of SFTS appeared to be effective, including the use of ribavirin, intravenous immunoglobulin, plasmapheresis, or continuous renal replacement therapy. Fungal pneumonia (n = 2, 6%) and cerebral hemorrhage (n = 2, 6%) were observed as complications among those who died.

Laboratory Features and Prognoses
---------------------------------

The laboratory data from the 32 patients with available medical records for the first 7 days after symptom onset are shown in [Table 3](#T3){ref-type="table"}. All patients had thrombocytopenia (platelets \<150 × 10^9^/L) and leukocytopenia (leukocytes \<4 × 10^9^ cells/L) on admission. The median minimum platelet count was marginally lower among those who died (34 × 10^9^/L), compared with that among those who recovered (47.5 × 10^9^/L; p = 0.054). The maximum serum aspartate aminotransferase, lactate dehydrogenase (LDH), creatinine kinase, and creatinine kinase myocardial b fraction levels were similar for both groups. However, the maximum alkaline phosphatase (ALP) levels during the first week after symptom onset were significantly higher for patients who died than for those who recovered (213 U/L vs. 79 U/L; p=0.017).

###### Laboratory features of hospitalized case-patients with confirmed severe fever with thrombocytopenia syndrome during the first week after onset, by outcome, South Korea, 2013\*

  ----------------------------------- ------------------ -------------------- ------------------ -------
  Laboratory tests                    Median (range)     p value†                                
  Total, n = 32                       Died, n = 14       Recovered, n = 18                       
  Platelet count, × 10^9^/L‡          38 (15--113)       34 (15--113)         47.5 (29--107)     0.054
  Leukocyte count, × 10^9^ cells/L‡   1.5 (0.7--3.0)     1.5 (0.7--3.0)       1.5 (0.7--2.7)     0.925
  ANC, × 10^6^ cells/L, n = 30‡       969 (125--3,292)   1,042 (380--2,367)   920 (125--3,292)   0.637
  Hemoglobin, g/L‡                    12.9 (9.2--16.4)   12.1 (9.2--15.1)     13.5 (9.8--16.4)   0.193
  aPTT, s, n = 30                     54 (35--97)        60 (35--97)          54 (36--73)        0.400
  AST, U/L, n = 31                    242 (63--4,567)    420 (103--4,567)     223 (63--2,145)    0.109
  ALT, U/L, n = 31                    77 (27--1,432)     156 (28--1,432)      63 (27--477)       0.186
  Total bilirubin, mg/dL, n = 31      0.5 (0.2--4.0)     0.6 (0.3--4.0)       0.5 (0.2--1.3)     0.109
  Amylase, U/L, n = 26                84 (40--333)       78 (49--163)         90 (40--333)       0.540
  Lipase, U/L, n = 20                 98 (38--692)       92 (38--369)         117 (40--692)      0.370
  CK, U/L, n = 21                     570 (67--4,362)    428 (158--4,362)     676 (67--2,760)    0.651
  CK-MB, U/L, n = 18                  6.9 (0.3--300.0)   4.8 (1.4--300.0)     7.6 (0.3--35.0)    0.762
  LDH, U/L, n = 28                    908 (279--4,564)   1,799 (279--4,564)   893 (348--3,920)   0.260
  ALP, U/L, n = 31                    119 (44--1,586)    213 (53--1,586)      79 (44--510)       0.017
  ----------------------------------- ------------------ -------------------- ------------------ -------

\*ANC, absolute neutrophil count; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatinine kinase; CK-MB, creatinine kinase myocardial b fraction; LDH, lactate dehydrogenase; ALP, alkaline phosphatase. †Mann-Whitney U test was used to compare groups. ‡Minimum value.

Discussion
==========

We found that SFTS cases occurred throughout South Korea, although the incidence was higher in the southern part of the country. Among the various clinical manifestations, neurologic symptoms (overall and within 7 days after disease onset) were substantially more frequent among the case-patients who died, although GI symptoms and hemorrhagic manifestations (except melena) were more frequent among those who recovered. No effective treatment, including ribavirin, was identified.

The higher incidence of SFTS in the southern part of South Korea was particularly notable for Jeju Province, which is the largest island and the most southern part of South Korea. The prevalence of *H. longicornis* ticks in Jeju Province is among of the highest in South Korea ([@R9],[@R10]); high temperatures are conducive to the survival and breeding of this species ([@R11]), and Jeju Province has the highest average temperature in South Korea, related to its low latitude ([@R12]). Furthermore, a study of ticks that were collected during 2011--2012 in South Korea reported that the minimum infection rates for SFTSV in *H. longicornis* ticks were higher in the southern part of the country ([@R6]).

Although the SFTS case-fatality rate in South Korea (46%) was higher than those that have been reported by using SFTS data from China (6%--30%) ([@R1],[@R13]), it was similar to the rate (55%) that was reported in a retrospective tracing study in Japan ([@R14]). However, after the introduction of the China surveillance system in 2009, a decreasing trend in the case-fatality rate in that country has been observed ([@R13]), which may be supported by the increased capability to detect mild SFTS cases. Age was associated with a prognosis of death in our study, and other studies of hospitalized patients in China with SFTS have reported similar findings ([@R15]--[@R17]). However, in our study, the median ages for those who died versus those who survived (73.5 years and 61 years, respectively) tended to be higher than those among the patients in China (62.1--74 years and 52.9--60 years, respectively) ([@R15]--[@R17]). This older age might partially explain why we observed a higher case-fatality rate compared with previous reports. However, we did not find any person-to-person clusters of infection, and found only 1 family cluster, although these patterns have been reported in China ([@R3],[@R18]).

The median time from symptom onset to admission was 4 days and from onset to clinical suspicion was 7 days. This finding indicates that there is a delay in diagnosis and appropriate care, which is likely related to lack of clinical experience with SFTS among physicians in South Korea. Nevertheless, despite the lack of a statistically significant relationship between this time period and death, a delayed diagnosis of SFTS could affect the prognosis of the patients.

The fever stage of SFTS occurs during the first week after disease onset and is characterized by the sudden onset of fever and GI symptoms ([@R19]); our findings were similar. However, we found that only 22% of those patients had a high fever (≥39°C), compared with 73% of hospitalized SFTS patients in China ([@R19]). Diarrhea was observed in 63% of patients in our study, which is higher than the 27%--57% rates that were observed in previous studies of hospitalized patients with SFTS ([@R1],[@R19],[@R20]). However, 43% of the patients in our study experienced vomiting, which is similar to the 31%--47% rates that were reported in the previous studies ([@R1],[@R19],[@R20]).

We found that neurologic symptoms were associated with a greater likelihood of death, and similar findings have been reported in previous studies of hospitalized patients in China ([@R19],[@R20]). Moreover, we observed a rapid progression and increased frequency of neurologic symptoms during the fever stage among the patients who died, suggesting that early neurologic symptoms portend a fatal outcome.

Hemorrhagic manifestations have been linked to fatal outcomes among SFTS patients in China ([@R19],[@R20]). However, we did not observe a similar association, with the exception of melena. Differences between the health care systems in South Korea and China, especially regarding the use of appropriate platelet transfusions, may partially explain the differences regarding hemorrhagic manifestations.

The lowest platelet counts during the first week were not substantively different between those who recovered and those who died. However, one study has reported that low platelet counts on admission or during the entire course were associated with SFTS severity ([@R20]). Therefore, it is possible that our relatively small number of cases may obscure the association of the lowest platelet counts with death among patients in South Korea.

According to 2 studies in China, elevated LDH levels on admission or during the entire course of illness were significantly associated with a fatal outcome ([@R15],[@R20]). However, we did not observe a significant association between the highest LDH levels during the first week or at the time of admission and death (data not shown). We did observe significantly higher ALP levels during the first week among those who died, although a study of ALP levels on admission reported similar levels between those who died and those who recovered on the basis of multivariate analysis findings ([@R15]). Additional studies are needed to evaluate the relationships between a prognosis of death and high levels of LDH or ALP.

Our study has several limitations. First, mild cases of SFTS might have been missed, given that all of our case-patients were hospitalized. Thus, the true case-fatality rate in South Korea is likely lower than our reported value, related to case ascertainment bias. Second, because of the limited number of SFTS cases during 2013, we could not perform multivariate analysis for the prognosis. Therefore, our findings should be interpreted with caution. Third, because of the case series design, we could not analyze the risk factors for SFTS infection.

In conclusion, the clinical symptoms of SFTS in South Korea appear similar to those experienced by hospitalized SFTS patients in China. Older age and early neurologic symptoms were associated with a fatal outcome in studies in both countries. Expansion of SFTS surveillance into the outpatient sector, along with the development and incorporation of an SFTSV antibody test into the case detection algorithm, would detect milder cases and enhance completeness of SFTS case detection in South Korea.
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